Kiora Pharmaceuticals Partners with B2i Digital to Enhance Investor Engagement

Advancing Novel Therapies to Restore Vision in Retinal Diseases

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage biotechnology company developing novel therapeutics to treat ophthalmic diseases that lead to vision loss. Headquartered in Encinitas, California, Kiora is focused on inherited retinal diseases like retinitis pigmentosa, choroideremia, and Stargardt's disease, as well as posterior non-infectious uveitis.

The company's lead asset, KIO-301, is designed to restore vision in these diseases by reactivating surviving retinal cells. Kiora recently announced preliminary data from a Phase 1b study of KIO-301 in retinitis pigmentosa patients that showed promising signs of bioactivity and plans to report complete results in the fourth quarter of 2023.

With an estimated patient population exceeding 150,000 in the U.S., Kiora is targeting retinal diseases with high unmet needs and multi-billion dollar market potential. The company expects to report data from several clinical trials over the next two years as it advances its pipeline. Kiora is led by an experienced management team and board of directors with decades of ophthalmology drug development expertise.

Kiora Pharmaceuticals Highlights

Kiora Pharmaceuticals offers several key strengths for investors to consider:

• Lead candidate KIO-301 is designed to restore vision in multiple inherited retinal diseases with high unmet need.
• Will report complete results from its Phase 1b trial of KIO-301 in retinitis pigmentosa patients in Q4 2023.
• Plans to initiate Phase 2 trials of KIO-301 in 2024 in retinitis pigmentosa and choroideremia.
• Advancing second candidate KIO-104 for posterior non-infectious uveitis.
• Targeting defined, rare patient populations in retinal diseases with multi-billion dollar market potential.
• Seasoned management team with decades of ophthalmology drug development experience.
• Strategic partnerships with patient advocacy groups to support clinical trial enrollment.

News Updates From Other B2i Featured Companies

Stay informed about recent updates from select Featured Companies and delve into their profiles for a more comprehensive overview.

Unicycive announced that recently published data highlights the benefits of its lead asset oxylanthanum carbonate (OLC) to potentially improve medication adherence and quality of life for patients with chronic kidney disease.

AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update

Treasure Global announced a letter of intent to form an e-commerce joint venture in Indonesia, marking a significant milestone in expanding its ZCITY app into the Indonesian market.

CareCloud announced a partnership with Google Cloud to integrate AI and Enterprise Search technology into its healthcare solutions, marking an important milestone for the industry.

TOP Ships Announces Management Estimate of Net Asset Value of $285 Million, Net Asset Value per Share of $14.02 and Diluted Net Asset Value per Share of $4.97

B2i Digital, Inc. provides digital marketing support to the above-mentioned Featured Companies, the Featured Companies hosted on b2idigital.com, and the Featured Conference companies hosted on b2idigital.com. B2i Digital has not independently verified the accuracy of the information contained herein or on b2idigital.com. The content was provided by the Companies or publicly available sources. B2I Digital, Inc. makes no warranties as to the accuracy of any information provided. No content contained herein or on b2idigital.com shall be considered an offer to solicit the sale of any security or be considered as an opinion as to its investment suitability. Please reference the full disclaimer at https://b2idigital.com/disclaimer.

We appreciate your interest in discovering more about our Featured Companies. We encourage you to explore our website, where you can access detailed profiles of all 18 Featured Companies and gain insights into the nearly 500 companies that have actively participated in our Featured Conferences.

Keep an eye out for updates on our upcoming Featured Conferences this fall, presented by Roth MKM, The Benchmark Company, Maxim Group, and other leaders in the industry.

Make the most of the remaining summer days, take some time to relax, and prepare yourself for what I anticipate will be a highly dynamic autumn season.

David Shapiro
Chief Executive Officer
B2i Digital, Inc.
212-579-4844 (office)
917-806-4171 (cell)

Connections are always welcome on LinkedIn.